In line with critical roles for ERCC1/XPF in ICL repair, we have previously shown that siRNA knockdown of ERCC1/XPF could enhance sensitivity of lung cancer cells to cisplatin [3]. This evidence concerns the gene ERCC1 and lung cancer.